Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Apple Restores Telegram to App Store After Content Policy Violation 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Telegram Restored on Apple App Store After Temporary Removal 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., April 09, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to its Senior Vice President and General Counsel, Mina Kim, effective as of April 9, 2018. Ms. Kim has nearly 20 years of corporate legal experience, most recently as the General Counsel of the publicly listed companies Sunrun Inc. and Fly Leasing Limited.
The compensation committee of Atara's board of directors granted Ms. Kim a stock option to purchase 70,000 shares of Atara’s common stock, and restricted stock units to acquire 42,500 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Ms. Kim entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $36.00, equal to the per share closing price of Atara's common stock as reported by Nasdaq on April 9, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-491-5806
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
